The combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) is approved to treat Braf V600E mutant melanoma patients (Robert et al., 2015; Long et al., 2017; Hauschild et al., 2018). This evidence concerns the gene BRAF and melanoma.